SAN MATEO

Kronos Bio Reports First-Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
CDK9, Investment, Research, KRON, Genentech, IND, ASCO, Therapy, Patient, Society, AACR, Adenoid cystic carcinoma, Cancer, SAN, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today reported recent business progress and financial results for the first-quarter of 2024.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today reported recent business progress and financial results for the first-quarter of 2024.
  • R&D Expenses: Research and development expenses were $14.2 million for the first quarter of 2024, which includes non-cash stock-based compensation expense of $1.2 million.
  • Impairment of Long-lived Assets and Restructuring: The Company incurred impairment of long-lived assets expense of $6.6 million for the first quarter of 2024.
  • The Company also incurred restructuring expense of $6.2 million for the first quarter of 2024, which includes non-cash stock-based compensation of $4.4 million.

BrightEdge Releases Latest Search Generative Experience (SGE) Data as Google Prepares for I/O

Retrieved on: 
星期四, 五月 9, 2024
Automation, Generative, Synthetic media, SGE, Rick Riordan, SAN, Motion, AI, Mobile phone

SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BrightEdge, the global leader in AI-driven organic search, content, and digital marketing automation, has released new data from the BrightEdge Generative Parser™.

Key Points: 
  • SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BrightEdge, the global leader in AI-driven organic search, content, and digital marketing automation, has released new data from the BrightEdge Generative Parser™.
  • “Google search has undergone massive changes in the past few months to test and perfect SGE, with the goal of providing the best possible search experience,” said BrightEdge founder and executive chair, Jim Yu.
  • Starting in mid-April, Google has significantly pulled back on the search queries where they are showing SGE results.
  • Since November 2023, BrightEdge Generative Parser™ has closely tracked Google SGE results and formats.

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline

Retrieved on: 
星期四, 五月 9, 2024
T. Rowe Price, HBM, HDV, New Board, Therapy, EMA, General partnership, Wellington Management Company, Series, SAN, Global health

SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round.

Key Points: 
  • SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round.
  • This capital infusion will accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV).
  • The funds will also support the progression of additional promising candidates in Bluejay's robust pipeline for the treatment for chronic hepatitis B.
  • Following the completion of the Series C financing, Bluejay is excited to welcome New Board Member, Daniel Estes, a General Partner at Frazier, to its Board of Directors.

Backblaze Announces First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 8, 2024
Cloud, Education, Motion, Investment, ARR, Film, Cloud storage, State, Phase 10, Yoy, Carahsoft, Webcast, National Association, Local government, TPN, SLED, NRR, SAN

SAN MATEO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Backblaze, Inc. (Nasdaq: BLZE), a leading specialized storage cloud platform, today announced results for its first quarter ended March 31, 2024.

Key Points: 
  • SAN MATEO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Backblaze, Inc. (Nasdaq: BLZE), a leading specialized storage cloud platform, today announced results for its first quarter ended March 31, 2024.
  • “We had a record start to 2024, with dramatically improved financial metrics year over year including Q1 revenue growth of 28% compared to 20%, and adjusted EBITDA margin of 6% versus -12%,” said Gleb Budman, CEO of Backblaze.
  • First Quarter 2024 Operational Highlights:
    Annual recurring revenue (ARR) was $122.1 million, an increase of 27% YoY.
  • Based on information available as of the date of this press release,
    For the second quarter of 2024 we expect:
    For full-year 2024 we expect:
    Today we announced that our Chief Financial Officer, Frank Patchel, plans to retire later this year.

Irion and Orion Governance Form a Partnership to Enhance the Advanced Enterprise Data Management Platform

Retrieved on: 
星期三, 五月 8, 2024
Partnership, Enterprise data management, Irion, Data management, Sales

San Mateo, California, May 08, 2024 (GLOBE NEWSWIRE) -- Irion , a leader in the Enterprise Data Management market and producer of Irion EDM, a unified data management platform and Orion Governance , the Information Intelligence Company, and provider of the Enterprise Information Intelligence Graph (EIIG), a self-defined data fabric, have reached a partnership agreement to leverage the synergies between the two companies to offer the most advanced enterprise data management solutions.

Key Points: 
  • San Mateo, California, May 08, 2024 (GLOBE NEWSWIRE) -- Irion , a leader in the Enterprise Data Management market and producer of Irion EDM, a unified data management platform and Orion Governance , the Information Intelligence Company, and provider of the Enterprise Information Intelligence Graph (EIIG), a self-defined data fabric, have reached a partnership agreement to leverage the synergies between the two companies to offer the most advanced enterprise data management solutions.
  • With this partnership agreement, Irion will enrich its offering with advanced metadata-management and data lineage capabilities from Orion Governance’s EIIG: Orion Governance’s intelligent and automated ingestors will further enhance Irion EDM capabilities of connecting with any data source and legacy application within a complex organization.
  • By leveraging Irion EDM functionalities, Orion Governance can also enhance its solutions and bring new value to their customers.
  • “EIIG’s core capabilities can further enhance Irion EDM’s active metadata management and data governance offerings.

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Retrieved on: 
星期二, 五月 7, 2024
University, FASN, EASL, Hepatology, F2, Patient, Fibrosis, SAN, Division, MASH

SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024.

Key Points: 
  • SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024.
  • General Session Oral Presentation Title: Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis.
  • Presenter: Rohit Loomba M.D., MHSc, ASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, United States

Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact from the Inflation Reduction Act

Retrieved on: 
星期二, 五月 7, 2024
Model, Medicare (United States), Medicare Part D, Model N, Inflation, Medicare, SAN, IRA, Health insurance

The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss.

Key Points: 
  • The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss.
  • Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.
  • Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025.
  • With continual enhancements to its suite of life sciences cloud solutions, Model N ensures pharma customers can nimbly adapt to evolving regulations while optimizing revenue.

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Retrieved on: 
星期一, 五月 6, 2024
University, CFO, FASN, Inflammation, École des ponts ParisTech, Compensated emancipation, Alexion Pharmaceuticals, Employment, Intercept Pharmaceuticals, Novartis, Engineering, Patient, Black–Scholes model, Acquisition, MBA, Sanofi, SAN, Strategic planning, Management

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.

Key Points: 
  • SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.
  • “We are thrilled to welcome Thierry to our executive leadership team in the role of CFO.
  • Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A,” said Dave Happel, CEO of Sagimet.
  • Before Provention Bio, Mr. Chauche was the Vice President and Head of Strategic Financial Planning & Analysis at Alexion Pharmaceuticals.

Model N Announces Date of Second Quarter Fiscal Year 2024 Financial Results

Retrieved on: 
星期四, 五月 2, 2024
Vista Equity Partners, Model N, Acquisition, SAN

SAN MATEO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Model N, Inc. (NYSE: MODN), a leader in revenue optimization and compliance, plans to announce financial results for the second quarter fiscal year 2024 pre-market on Monday, May 6, 2024.

Key Points: 
  • SAN MATEO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Model N, Inc. (NYSE: MODN), a leader in revenue optimization and compliance, plans to announce financial results for the second quarter fiscal year 2024 pre-market on Monday, May 6, 2024.
  • Due to the Company’s pending acquisition by Vista Equity Partners that was announced on April 8, 2024, there will not be a conference call or live webcast to discuss the financial results.

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
星期三, 四月 24, 2024
Cancer, CDK9, Safety, KRON, ASCO, Society, AACR, Annual general meeting, SAN, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 ( NCT04718675 ), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 ( NCT04718675 ), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 – June 4, 2024 in Chicago, Illinois and online.
  • “We are looking forward to sharing updated data from KB-0742-1001, our ongoing Phase 1/2 trial of KB-0742, including data from the 80mg three days on/four days off dosing regimen.
  • The trial is designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of KB-0742, an orally bioavailable and selective CDK9 inhibitor with a long half-life,” said Norbert Bischofberger, Ph.D., chief executive officer and president of Kronos Bio.
  • “Our last update at the 2023 AACR-NCI-EORTC meeting showed that KB-0742 exhibited anti-tumor activity while maintaining an acceptable safety profile at the 60mg three-days-on, four-days-off dose, which is an important step as we seek to identify the optimal dose of KB-0742.”
    Details for the ASCO 2024 abstract are as follows: